Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency.

Wingender G, Krebs P, Beutler B, Kronenberg M.

J Immunol. 2010 Sep 1;185(5):2721-9. doi: 10.4049/jimmunol.1001018. Epub 2010 Jul 26.

2.

CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.

Hayworth JL, Mazzuca DM, Maleki Vareki S, Welch I, McCormick JK, Haeryfar SM.

Immunol Cell Biol. 2012 Aug;90(7):699-709. doi: 10.1038/icb.2011.90. Epub 2011 Nov 1.

PMID:
22041925
3.

Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation.

Cullen R, Germanov E, Shimaoka T, Johnston B.

J Immunol. 2009 Nov 1;183(9):5807-15. doi: 10.4049/jimmunol.0803520. Epub 2009 Oct 7.

4.

PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.

Parekh VV, Lalani S, Kim S, Halder R, Azuma M, Yagita H, Kumar V, Wu L, Kaer LV.

J Immunol. 2009 Mar 1;182(5):2816-26. doi: 10.4049/jimmunol.0803648.

5.

Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.

Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.

J Immunol. 2002 Apr 1;168(7):3484-92.

6.

NKG2A inhibits invariant NKT cell activation in hepatic injury.

Kawamura T, Takeda K, Kaneda H, Matsumoto H, Hayakawa Y, Raulet DH, Ikarashi Y, Kronenberg M, Yagita H, Kinoshita K, Abo T, Okumura K, Smyth MJ.

J Immunol. 2009 Jan 1;182(1):250-8.

7.

NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.

Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt R, Harris AL, Old L, Cerundolo V.

J Immunol. 2003 Nov 15;171(10):5140-7.

8.

The development of airway hyperreactivity in T-bet-deficient mice requires CD1d-restricted NKT cells.

Kim HY, Pichavant M, Matangkasombut P, Koh YI, Savage PB, DeKruyff RH, Umetsu DT.

J Immunol. 2009 Mar 1;182(5):3252-61. doi: 10.4049/jimmunol.0803339.

9.

Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells.

Li X, Shiratsuchi T, Chen G, Dellabona P, Casorati G, Franck RW, Tsuji M.

J Immunol. 2009 Oct 1;183(7):4415-21. doi: 10.4049/jimmunol.0901021. Epub 2009 Sep 4. Erratum in: J Immunol. 2010 Jan 15;184(2):1121.

10.

Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides.

Ortaldo JR, Young HA, Winkler-Pickett RT, Bere EW Jr, Murphy WJ, Wiltrout RH.

J Immunol. 2004 Jan 15;172(2):943-53.

11.

Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity.

Wu J, Shin J, Xie D, Wang H, Gao J, Zhong XP.

J Immunol. 2014 Mar 15;192(6):2643-50. doi: 10.4049/jimmunol.1302076. Epub 2014 Feb 14.

12.

Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis.

Mallevaey T, Fontaine J, Breuilh L, Paget C, Castro-Keller A, Vendeville C, Capron M, Leite-de-Moraes M, Trottein F, Faveeuw C.

Infect Immun. 2007 May;75(5):2171-80. Epub 2007 Mar 12.

13.

Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.

Nakagawa R, Nagafune I, Tazunoki Y, Ehara H, Tomura H, Iijima R, Motoki K, Kamishohara M, Seki S.

J Immunol. 2001 Jun 1;166(11):6578-84.

15.

Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.

Frost PJ, Butterfield LH, Dissette VB, Economou JS, Bonavida B.

J Immunol. 2001 Mar 1;166(5):3564-73.

16.

Human CD4+ invariant NKT cells are involved in antibacterial immunity against Brucella suis through CD1d-dependent but CD4-independent mechanisms.

Bessoles S, Dudal S, Besra GS, Sanchez F, Lafont V.

Eur J Immunol. 2009 Apr;39(4):1025-35. doi: 10.1002/eji.200838929.

17.

The presence of CD8+ invariant NKT cells in mice.

Lee H, Hong C, Shin J, Oh S, Jung S, Park YK, Hong S, Lee GR, Park SH.

Exp Mol Med. 2009 Dec 31;41(12):866-72. doi: 10.3858/emm.2009.41.12.092.

18.

Pathogen-expanded CD11b+ invariant NKT cells feedback inhibit T cell proliferation via membrane-bound TGF-β1.

Han Y, Jiang Z, Chen Z, Gu Y, Liu Y, Zhang X, Cao X.

J Autoimmun. 2015 Apr;58:21-35. doi: 10.1016/j.jaut.2014.12.006. Epub 2015 Jan 13.

PMID:
25592391
19.

Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.

Stuart JK, Bisch SP, Leon-Ponte M, Hayatsu J, Mazzuca DM, Maleki Vareki S, Haeryfar SM.

Int Immunopharmacol. 2010 Sep;10(9):1068-76. doi: 10.1016/j.intimp.2010.06.007. Epub 2010 Jun 11.

PMID:
20584631
20.

The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.

Pyz E, Naidenko O, Miyake S, Yamamura T, Berberich I, Cardell S, Kronenberg M, Herrmann T.

J Immunol. 2006 Jun 15;176(12):7447-55.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk